Sponsored Links
BRIEF-Vanda Pharma jumps in premarket after drug for rare disorder meets main trial goal
NEW YORK |
NEW YORK Dec 18 (Reuters) - Vanda Pharmaceuticals Inc : * Pharma jumps 30.1 percent to $4.19 in premarket after drug for non-24-hour disorder, which affects blind people, met the main goal of showing improvement over a placebo
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters